Issue

Vol. 17 (2025)

Engineered Cancer Nanovaccines: A New Frontier in Cancer Therapy

https://doi.org/10.1007/s40820-024-01533-y
Yijie Wang
Central Laboratory and Department of Medical Ultrasound, Sichuan Academy of Medical Sciences, Sichuan Provincial People’s Hospital, School of Medicine, University of Electronic Science and Technology of China, No. 32, West Second Section, First Ring Road, Chengdu 610072, People’s Republic of China
Congrui Liu
Central Laboratory and Department of Medical Ultrasound, Sichuan Academy of Medical Sciences, Sichuan Provincial People’s Hospital, School of Medicine, University of Electronic Science and Technology of China, No. 32, West Second Section, First Ring Road, Chengdu 610072, People’s Republic of China
Chao Fang
Central Laboratory and Department of Medical Ultrasound, Sichuan Academy of Medical Sciences, Sichuan Provincial People’s Hospital, School of Medicine, University of Electronic Science and Technology of China, No. 32, West Second Section, First Ring Road, Chengdu 610072, People’s Republic of China
Qiuxia Peng
Central Laboratory and Department of Medical Ultrasound, Sichuan Academy of Medical Sciences, Sichuan Provincial People’s Hospital, School of Medicine, University of Electronic Science and Technology of China, No. 32, West Second Section, First Ring Road, Chengdu 610072, People’s Republic of China
Wen Qin
Central Laboratory and Department of Medical Ultrasound, Sichuan Academy of Medical Sciences, Sichuan Provincial People’s Hospital, School of Medicine, University of Electronic Science and Technology of China, No. 32, West Second Section, First Ring Road, Chengdu 610072, People’s Republic of China
Xuebing Yan
Jiangsu Provincial Innovation and Practice Base for Postdoctors, Suining People’s Hospital, Affiliated Hospital of Xuzhou Medical University, No.2, Bayi West Road, Suining, Xu Zhou 221000, Jiangsu Province, People’s Republic of China
Kun Zhang
Central Laboratory and Department of Medical Ultrasound, Sichuan Academy of Medical Sciences, Sichuan Provincial People’s Hospital, School of Medicine, University of Electronic Science and Technology of China, No. 32, West Second Section, First Ring Road, Chengdu 610072, People’s Republic of China

Corresponding Author: Kun Zhang

zhang1986kun@126.com

Nano-Micro Letters, Vol. 17 (2025), Article Number: 30

Abstract

Vaccinations are essential for preventing and treating disease, especially cancer nanovaccines, which have gained considerable interest recently for their strong anti-tumor immune capabilities. Vaccines can prompt the immune system to generate antibodies and activate various immune cells, leading to a response against tumor tissues and reducing the negative effects and recurrence risks of traditional chemotherapy and surgery. To enhance the flexibility and targeting of vaccines, nanovaccines utilize nanotechnology to encapsulate or carry antigens at the nanoscale level, enabling more controlled and precise drug delivery to enhance immune responses. Cancer nanovaccines function by encapsulating tumor-specific antigens or tumor-associated antigens within nanomaterials. The small size of these nanomaterials allows for precise targeting of T cells, dendritic cells, or cancer cells, thereby eliciting a more potent anti-tumor response. In this paper, we focus on the classification of carriers for cancer nanovaccines, the roles of different target cells, and clinically tested cancer nanovaccines, discussing strategies for effectively inducing cytotoxic T lymphocytes responses and optimizing antigen presentation, while also looking ahead to the translational challenges of moving from animal experiments to clinical trials.


Highlights:
1 We classified the carriers that built cancer nanovaccines, discussed their diversified applications and coincidently compared their advantages and disadvantages.
2 Various cellular targets that guide the design and engineering of cancer nanovaccines are categorized and their characteristics and benefits are highlighted.
3 The clinical cases and encountered challenges in cancer nanovaccines are discussed, during which reasonable solutions and future research direction are provided.

Keywords

Cancer nanovaccines Immunotherapy Nanobiotechnology Immune targets Signaling pathway
Wang, Yijie, Congrui Liu, Chao Fang, Qiuxia Peng, Wen Qin, Xuebing Yan, and Kun Zhang. 2024. “Engineered Cancer Nanovaccines: A New Frontier in Cancer Therapy”. Nano-Micro Letters 17 (September):30. https://doi.org/10.1007/s40820-024-01533-y.
Download Citation
Endnote/Zotero/Mendeley (RIS)
BibTeX
References
  1. S.A. Plotkin, Vaccines: past, present and future. Nat. Med. 11(4 Suppl), S5–S11 (2005). https://doi.org/10.1038/nm1209
  2. I. Delany, R. Rappuoli, E. De Gregorio, Vaccines for the 21st century. EMBO Mol. Med. 6, 708–720 (2014). https://doi.org/10.1002/emmm.201403876
  3. D. Ndwandwe, C.S. Wiysonge, Covid-19 vaccines. Curr. Opin. Immunol. 71, 111–116 (2021). https://doi.org/10.1016/j.coi.2021.07.003
  4. P. Zamani, J.G. Navashenaq, A.R. Nikpoor, M. Hatamipour, R.K. Oskuee et al., MPL nano-liposomal vaccine containing P5 HER2/neu-derived peptide pulsed PADRE as an effective vaccine in a mice TUBO model of breast cancer. J. Control. Release 303, 223–236 (2019). https://doi.org/10.1016/j.jconrel.2019.04.019
  5. M.Z. Ahmad, J. Ahmad, A. Haque, M.Y. Alasmary, B.A. Abdel-Wahab et al., Emerging advances in synthetic cancer nano-vaccines: opportunities and challenges. Expert Rev. Vaccines 19, 1053–1071 (2020). https://doi.org/10.1080/14760584.2020.1858058
  6. K.L. Hess, I.L. Medintz, C.M. Jewell, Designing inorganic nanomaterials for vaccines and immunotherapies. Nano Today 27, 73–98 (2019). https://doi.org/10.1016/j.nantod.2019.04.005
  7. J. Chen, Z. Ye, C. Huang, M. Qiu, D. Song et al., Lipid nanop-mediated lymph node-targeting delivery of mRNA cancer vaccine elicits robust CD8(+) T cell response. Proc. Natl. Acad. Sci. U.S.A. 119, e2207841119 (2022). https://doi.org/10.1073/pnas.2207841119
  8. A.M. Reichmuth, M.A. Oberli, A. Jaklenec, R. Langer, D. Blankschtein, mRNA vaccine delivery using lipid nanops. Ther. Deliv. 7, 319–334 (2016). https://doi.org/10.4155/tde-2016-0006
  9. A. Bolhassani, S. Javanzad, T. Saleh, M. Hashemi, M.R. Aghasadeghi et al., Polymeric nanops: potent vectors for vaccine delivery targeting cancer and infectious diseases. Hum. Vaccin. Immunother. 10, 321–332 (2014). https://doi.org/10.4161/hv.26796
  10. J. Han, D. Zhao, D. Li, X. Wang, Z. Jin et al., Polymer-based nanomaterials and applications for vaccines and drugs. Polymers 10, 31 (2018). https://doi.org/10.3390/polym10010031
  11. R. Harrop, J. John, M.W. Carroll, Recombinant viral vectors: cancer vaccines. Adv. Drug Deliv. Rev. 58, 931–947 (2006). https://doi.org/10.1016/j.addr.2006.05.005
  12. H. Wu, H. Li, Y. Liu, J. Liang, Q. Liu et al., Blockading a new NSCLC immunosuppressive target by pluripotent autologous tumor vaccines magnifies sequential immunotherapy. Bioact. Mater. 13, 223–238 (2021). https://doi.org/10.1016/j.bioactmat.2021.10.048
  13. X. Dong, Q. Yang, H. Wang, C. Zhu, T. Wang et al., Targetedly attenuating cancer stemness and plasticity by homologous cancer stem cell-inherited fusion membrane nanoeffectors against cancer metastasis. Small Sci. 4, 2300111 (2024). https://doi.org/10.1002/smsc.202300111
  14. C. Feng, Y. Li, B.E. Ferdows, D.N. Patel, J. Ouyang et al., Emerging vaccine nanotechnology: from defense against infection to sniping cancer. Acta Pharm. Sin. B 12, 2206–2223 (2022). https://doi.org/10.1016/j.apsb.2021.12.021
  15. C.L. Chiang, L.E. Kandalaft, In vivo cancer vaccination: which dendritic cells to target and how? Cancer Treat. Rev. 71, 88–101 (2018). https://doi.org/10.1016/j.ctrv.2018.10.012
  16. M. Saxena, S. Balan, V. Roudko, N. Bhardwaj, Towards superior dendritic-cell vaccines for cancer therapy. Nat. Biomed. Eng. 2, 341–346 (2018). https://doi.org/10.1038/s41551-018-0250-x
  17. X. Huang, X. Zhu, H. Yang, Q. Li, L. Gai et al., Nanomaterial delivery vehicles for the development of neoantigen tumor vaccines for personalized treatment. Molecules 29, 1462 (2024). https://doi.org/10.3390/molecules29071462
  18. T. Wang, M. Han, Y. Han, Z. Jiang, Q. Zheng et al., Antigen self-presented personalized nanovaccines boost the immunotherapy of highly invasive and metastatic tumors. ACS Nano 18, 6333–6347 (2024). https://doi.org/10.1021/acsnano.3c11189
  19. H. Wang, X. Wu, Y. Sun, A. Liu, Y. He et al., A natural IgM hitchhiking strategy for delivery of cancer nanovaccines to splenic marginal zone B cells. J. Control. Release 368, 208–218 (2024). https://doi.org/10.1016/j.jconrel.2024.02.029
  20. Y. Dölen, M. Valente, O. Tagit, E. Jäger, E.A.W. Van Dinther et al., Nanovaccine administration route is critical to obtain pertinent iNKt cell help for robust anti-tumor T and B cell responses. Oncoimmunology 9, 1738813 (2020). https://doi.org/10.1080/2162402X.2020.1738813
  21. A. Gül, M. Döşkaya, H. Can, M. Karakavuk, M. Anıl-İnevi et al., Immunogenicity of a xenogeneic multi-epitope HER2+ breast cancer DNA vaccine targeting the dendritic cell restricted antigen-uptake receptor DEC205. Vaccine 40, 2409–2419 (2022). https://doi.org/10.1016/j.vaccine.2022.03.014
  22. L. Ma, L. Diao, Z. Peng, Y. Jia, H. Xie et al., Immunotherapy and prevention of cancer by nanovaccines loaded with whole-cell components of tumor tissues or cells. Adv. Mater. 33, 2104849 (2021). https://doi.org/10.1002/adma.202104849
  23. M. Saxena, S.H. van der Burg, C.J.M. Melief, N. Bhardwaj, Therapeutic cancer vaccines. Nat. Rev. Cancer 21, 360–378 (2021). https://doi.org/10.1038/s41568-021-00346-0
  24. R.L. Atmar, W.A. Keitel, Searching for improved flu vaccines-the time is now. J. Infect. Dis. 221, 1–4 (2020). https://doi.org/10.1093/infdis/jiz545
  25. A.S. Bandyopadhyay, J. Garon, K. Seib, W.A. Orenstein, Polio vaccination: past, present and future. Future Microbiol. 10, 791–808 (2015). https://doi.org/10.2217/fmb.15.19
  26. D.E. Griffin, Measles vaccine. Viral Immunol. 31, 86–95 (2018). https://doi.org/10.1089/vim.2017.0143
  27. A.M. Galazka, S.E. Robertson, A. Kraigher, Mumps and mumps vaccine: a global review. Bull. World Health Organ. 77, 3–14 (1999). https://www.ncbi.nlm.nih.gov/pmc/s/PMC2557572/pdf/10063655.pdf
  28. N. Lambert, P. Strebel, W. Orenstein, J. Icenogle, G.A. Poland, Rubella. Lancet 385, 2297–2307 (2015). https://doi.org/10.1016/S0140-6736(14)60539-0
  29. H. Zhao, X. Zhou, Y.-H. Zhou, Hepatitis B vaccine development and implementation. Hum. Vaccines Immunother. 16, 1533–1544 (2020). https://doi.org/10.1080/21645515.2020.1732166
  30. M. Stanley, Immunobiology of HPV and HPV vaccines. Gynecol. Oncol. 109, S15–S21 (2008). https://doi.org/10.1016/j.ygyno.2008.02.003
  31. M. Li, H. Wang, L. Tian, Z. Pang, Q. Yang et al., COVID-19 vaccine development: milestones, lessons and prospects. Signal Transduct. Target. Ther. 7, 146 (2022). https://doi.org/10.1038/s41392-022-00996-y
  32. J. Liu, M. Fu, M. Wang, D. Wan, Y. Wei et al., Cancer vaccines as promising immuno-therapeutics: platforms and current progress. J. Hematol. Oncol. 15, 28 (2022). https://doi.org/10.1186/s13045-022-01247-x
  33. H.C. Hoover Jr., M.G. Surdyke, R.B. Dangel, L.C. Peters, M.G. Hanna Jr., Prospectively randomized trial of adjuvant active-specific immunotherapy for human colorectal cancer. Cancer 55, 1236–1243 (1985). https://doi.org/10.1002/1097-0142(19850315)55:6<1236::aid-cncr2820550616>3.0.co;2-#
  34. P. van der Bruggen, C. Traversari, P. Chomez, C. Lurquin, E. De Plaen et al., A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 254, 1643–1647 (1991). https://doi.org/10.1126/science.1840703
  35. T.A. Gardner, B.D. Elzey, N.M. Hahn, Sipuleucel-T (Provenge) autologous vaccine approved for treatment of men with asymptomatic or minimally symptomatic castrate-resistant metastatic prostate cancer. Hum. Vaccin. Immunother. 8, 534–539 (2012). https://doi.org/10.4161/hv.19795
  36. K. Liang, Y. Sun, L. Xie, Y. Liu, Y. You et al., Biologically self-assembled tumor cell-derived cancer nanovaccines as an all-in-one platform for cancer immunotherapy. ACS Nano 18, 6702–6717 (2024). https://doi.org/10.1021/acsnano.4c01050
  37. J. Pan, Y. Wang, C. Zhang, X. Wang, H. Wang et al., Antigen-directed fabrication of a multifunctional nanovaccine with ultrahigh antigen loading efficiency for tumor photothermal-immunotherapy. Adv. Mater. 30, 1704408 (2018). https://doi.org/10.1002/adma.201704408
  38. L.A. Dykman, Gold nanops for preparation of antibodies and vaccines against infectious diseases. Expert Rev. Vaccines 19, 465–477 (2020). https://doi.org/10.1080/14760584.2020.1758070
  39. Y. Zhao, X. Zhao, Y. Cheng, X. Guo, W. Yuan, Iron oxide nanops-based vaccine delivery for cancer treatment. Mol. Pharm. 15, 1791–1799 (2018). https://doi.org/10.1021/acs.molpharmaceut.7b01103
  40. X. Hong, X. Zhong, G. Du, Y. Hou, Y. Zhang et al., The pore size of mesoporous silica nanops regulates their antigen delivery efficiency. Sci. Adv. 6, eaaz4462 (2020). https://doi.org/10.1126/sciadv.aaz4462
  41. J. Sun, F. Liu, W. Yu, D. Fu, Q. Jiang et al., Visualization of vaccine dynamics with quantum dots for immunotherapy. Angew. Chem. Int. Ed. 60, 24275–24283 (2021). https://doi.org/10.1002/anie.202111093
  42. T. Wang, M. Zou, H. Jiang, Z. Ji, P. Gao et al., Synthesis of a novel kind of carbon nanop with large mesopores and macropores and its application as an oral vaccine adjuvant. Eur. J. Pharm. Sci. 44, 653–659 (2011). https://doi.org/10.1016/j.ejps.2011.10.012
  43. X. Li, X. Wang, A. Ito, Tailoring inorganic nanoadjuvants towards next-generation vaccines. Chem. Soc. Rev. 47, 4954–4980 (2018). https://doi.org/10.1039/C8CS00028J
  44. C.A. Bohannon, A.J. Chancellor, M.T. Kelly, T.T. Le, L. Zhu et al., Adaptable multivalent hairy inorganic nanops. J. Am. Chem. Soc. 143, 16919–16924 (2021). https://doi.org/10.1021/jacs.1c08261
  45. T. Zhao, Y. Cai, Y. Jiang, X. He, Y. Wei et al., Vaccine adjuvants: mechanisms and platforms. Signal Transduct. Target. Ther. 8, 283 (2023). https://doi.org/10.1038/s41392-023-01557-7
  46. F. Soetaert, P. Korangath, D. Serantes, S. Fiering, R. Ivkov, Cancer therapy with iron oxide nanops: agents of thermal and immune therapies. Adv. Drug Deliv. Rev. 163–164, 65–83 (2020). https://doi.org/10.1016/j.addr.2020.06.025
  47. S. Zanganeh, G. Hutter, R. Spitler, O. Lenkov, M. Mahmoudi et al., Iron oxide nanops inhibit tumour growth by inducing pro-inflammatory macrophage polarization in tumour tissues. Nat. Nanotechnol. 11, 986–994 (2016). https://doi.org/10.1038/nnano.2016.168
  48. G. Liu, J. Gao, H. Ai, X. Chen, Applications and potential toxicity of magnetic iron oxide nanops. Small 9, 1533–1545 (2013). https://doi.org/10.1002/smll.201201531
  49. F.P. García de Arquer, D.V. Talapin, V.I. Klimov, Y. Arakawa, M. Bayer et al., Semiconductor quantum dots: technological progress and future challenges. Science 373, eaaz8541 (2021). https://doi.org/10.1126/science.aaz8541
  50. R.E. Bailey, A.M. Smith, S. Nie, Quantum dots in biology and medicine. Phys. E Low Dimension. Syst. Nanostruct. 25, 1–12 (2004). https://doi.org/10.1016/j.physe.2004.07.013
  51. V.G. Reshma, P.V. Mohanan, Quantum dots: applications and safety consequences. J. Lumin. 205, 287–298 (2019). https://doi.org/10.1016/j.jlumin.2018.09.015
  52. N. Amonov, E.S. Ch, G. Abduraimova, Analysis of research on the properties, production and use of carbon nanops. Miasto Przyszłości. 28, 136–138 (2022)
  53. B.J. Panessa-Warren, J.B. Warren, S.S. Wong, J.A. Misewich, Biological cellular response to carbon nanop toxicity. J. Phys. Condens. Matter 18, S2185–S2201 (2006). https://doi.org/10.1088/0953-8984/18/33/s34
  54. S. Fiorito, A. Serafino, F. Andreola, A. Togna, G. Togna, Toxicity and biocompatibility of carbon nanops. J. Nanosci. Nanotechnol. 6, 591–599 (2006). https://doi.org/10.1166/jnn.2006.125
  55. J. Ni, J. Song, B. Wang, H. Hua, H. Zhu et al., Dendritic cell vaccine for the effective immunotherapy of breast cancer. Biomed. Pharmacother. 126, 110046 (2020). https://doi.org/10.1016/j.biopha.2020.110046
  56. L. Huang, Y. Liao, C. Li, Z. Ma, Z. Liu, Multifunctional manganese-containing vaccine delivery system Ca@MnCO3/LLO for tumor immunotherapy. Biomater. Adv. 136, 212752 (2022). https://doi.org/10.1016/j.bioadv.2022.212752
  57. B. García-Pinel, C. Porras-Alcalá, A. Ortega-Rodríguez, F. Sarabia, J. Prados et al., Lipid-based nanops: application and recent advances in cancer treatment. Nanomaterials 9, 638 (2019). https://doi.org/10.3390/nano9040638
  58. M.-G. Alameh, I. Tombácz, E. Bettini, K. Lederer, C. Sittplangkoon et al., Lipid nanops enhance the efficacy of mRNA and protein subunit vaccines by inducing robust T follicular helper cell and humoral responses. Immunity 54, 2877-2892.e7 (2021). https://doi.org/10.1016/j.immuni.2021.11.001
  59. J. Pardeike, A. Hommoss, R.H. Müller, Lipid nanops (SLN, NLC) in cosmetic and pharmaceutical dermal products. Int. J. Pharm. 366, 170–184 (2009). https://doi.org/10.1016/j.ijpharm.2008.10.003
  60. Y. Xia, S. Fu, Q. Ma, Y. Liu, N. Zhang, Application of nano-delivery systems in lymph nodes for tumor immunotherapy. Nano-Micro Lett. 15, 145 (2023). https://doi.org/10.1007/s40820-023-01125-2
  61. D. Sivadasan, K. Ramakrishnan, J. Mahendran, H. Ranganathan, A. Karuppaiah et al., Solid lipid nanops: applications and prospects in cancer treatment. Int. J. Mol. Sci. 24, 6199 (2023). https://doi.org/10.3390/ijms24076199
  62. Y. Mirchandani, V.B. Patravale, S. Brijesh, Solid lipid nanops for hydrophilic drugs. J. Control. Release 335, 457–464 (2021). https://doi.org/10.1016/j.jconrel.2021.05.032
  63. V.J. Lingayat, N.S. Zarekar, R.S. Shendge, Solid lipid nanops: a review. Nanosci. Nanotechnol. Res. 4, 67–72 (2017). https://doi.org/10.12691/nnr-4-2-5
  64. A. Sharma, Nanocomposite materials for biomedical and energy storage applications. (BoD–Books on Demand; 2022). https://doi.org/10.5772/intechopen.95130
  65. A. Beloqui, M.Á. Solinís, A. Rodríguez-Gascón, A.J. Almeida, V. Préat, Nanostructured lipid carriers: promising drug delivery systems for future clinics. Nanomed. Nanotechnol. Biol. Med. 12, 143–161 (2016). https://doi.org/10.1016/j.nano.2015.09.004
  66. M. Elmowafy, M.M. Al-Sanea, Nanostructured lipid carriers (NLCs) as drug delivery platform: advances in formulation and delivery strategies. Saudi Pharm. J. 29, 999–1012 (2021). https://doi.org/10.1016/j.jsps.2021.07.015
  67. H. Kang, S. Rho, W.R. Stiles, S. Hu, Y. Baek et al., Size-dependent EPR effect of polymeric nanops on tumor targeting. Adv. Healthc. Mater. 9, 1901223 (2020). https://doi.org/10.1002/adhm.201901223
  68. R. Han, J. Zhu, X. Yang, H. Xu, Surface modification of poly(D, L-lactic-co-glycolic acid) nanops with protamine enhanced cross-presentation of encapsulated ovalbumin by bone marrow-derived dendritic cells. J. Biomed. Mater. Res. A 96, 142–149 (2011). https://doi.org/10.1002/jbm.a.32860
  69. W.-S. Cho, F. Thielbeer, R. Duffin, E.M.V. Johansson, I.L. Megson et al., Surface functionalization affects the Zeta potential, coronal stability and membranolytic activity of polymeric nanops. Nanotoxicology 8, 202–211 (2014). https://doi.org/10.3109/17435390.2013.773465
  70. C. He, Y. Hu, L. Yin, C. Tang, C. Yin, Effects of p size and surface charge on cellular uptake and biodistribution of polymeric nanops. Biomaterials 31, 3657–3666 (2010). https://doi.org/10.1016/j.biomaterials.2010.01.065
  71. A. Gutjahr, C. Phelip, A.-L. Coolen, C. Monge, A.-S. Boisgard et al., Biodegradable polymeric nanops-based vaccine adjuvants for lymph nodes targeting. Vaccines 4, 34 (2016). https://doi.org/10.3390/vaccines4040034
  72. M. Kumar, A.K. Behera, R.F. Lockey, J. Zhang, G. Bhullar et al., Intranasal gene transfer by chitosan-DNA nanospheres protects BALB/c mice against acute respiratory syncytial virus infection. Hum. Gene Ther. 13, 1415–1425 (2002). https://doi.org/10.1089/10430340260185058
  73. M. Iqbal, W. Lin, I. Jabbal-Gill, S.S. Davis, M.W. Steward et al., Nasal delivery of chitosan-DNA plasmid expressing epitopes of respiratory syncytial virus (RSV) induces protective CTL responses in BALB/c mice. Vaccine 21, 1478–1485 (2003). https://doi.org/10.1016/s0264-410x(02)00662-x
  74. E.C. Carroll, L. Jin, A. Mori, N. Muñoz-Wolf, E. Oleszycka et al., The vaccine adjuvant chitosan promotes cellular immunity via DNA sensor cGAS-STING-dependent induction of type I interferons. Immunity 44, 597–608 (2016). https://doi.org/10.1016/j.immuni.2016.02.004
  75. K.H. Wong, A. Lu, X. Chen, Z. Yang, Natural ingredient-based polymeric nanops for cancer treatment. Molecules 25, 3620 (2020). https://doi.org/10.3390/molecules25163620
  76. J.I. Bussio, C. Molina-Perea, J.V. González-Aramundiz, Hyaluronic acid nanocapsules as a platform for needle-free vaccination. Pharmaceutics 11, 246 (2019). https://doi.org/10.3390/pharmaceutics11050246
  77. J. Yang, Y. Luo, M.A. Shibu, I. Toth, M. Skwarczynskia, Cell-penetrating peptides: efficient vectors for vaccine delivery. Curr. Drug Deliv. 16, 430–443 (2019). https://doi.org/10.2174/1567201816666190123120915
  78. Q. Liu, J. Jia, T. Yang, Q. Fan, L. Wang et al., Pathogen-mimicking polymeric nanops based on dopamine polymerization as vaccines adjuvants induce robust humoral and cellular immune responses. Small 12, 1744–1757 (2016). https://doi.org/10.1002/smll.201503662
  79. Q. Su, C. Wang, H. Song, C. Zhang, J. Liu et al., Co-delivery of anionic epitope/CpG vaccine and IDO inhibitor by self-assembled cationic liposomes for combination melanoma immunotherapy. J. Mater. Chem. B 9, 3892–3899 (2021). https://doi.org/10.1039/d1tb00256b
  80. Y. Gao, Y. Liu, X. Li, H. Wang, Y. Yang et al., A stable open-shell conjugated diradical polymer with ultra-high photothermal conversion efficiency for NIR-II photo-immunotherapy of metastatic tumor. Nano-Micro Lett. 16, 21 (2023). https://doi.org/10.1007/s40820-023-01219-x
  81. T. Lima, K. Bernfur, M. Vilanova, T. Cedervall, Understanding the lipid and protein Corona formation on different sized polymeric nanops. Sci. Rep. 10, 1129 (2020). https://doi.org/10.1038/s41598-020-57943-6
  82. J.A. Jackman, B.K. Yoon, L. Ouyang, W. Nan, A.R. Ferhan et al., Biomimetic nanomaterial strategies for virus targeting: antiviral therapies and vaccines. Adv. Funct. Mater. 31, 2008352 (2021). https://doi.org/10.1002/adfm.202008352
  83. K.G. Gareev, D.S. Grouzdev, V.V. Koziaeva, N.O. Sitkov, H. Gao et al., Biomimetic nanomaterials: diversity, technology, and biomedical applications. Nanomaterials 12, 2485 (2022). https://doi.org/10.3390/nano12142485
  84. C. Feng, P. Tan, G. Nie, M. Zhu, Biomimetic and bioinspired nano-platforms for cancer vaccine development. Exploration (Beijing) 3, 20210263 (2023). https://doi.org/10.1002/EXP.20210263
  85. J. Su, H. Sun, Q. Meng, Q. Yin, S. Tang et al., Long circulation red-blood-cell-mimetic nanops with peptide-enhanced tumor penetration for simultaneously inhibiting growth and lung metastasis of breast cancer. Adv. Funct. Mater. 30, 1910229 (2020). https://doi.org/10.1002/adfm.201910229
  86. M. Xuan, J. Shao, J. Zhao, Q. Li, L. Dai et al., Magnetic mesoporous silica nanops cloaked by red blood cell membranes: applications in cancer therapy. Angew. Chem. Int. Ed. 57, 6049–6053 (2018). https://doi.org/10.1002/anie.201712996
  87. J. Li, S. Wang, X. Lin, Y. Cao, Z. Cai et al., Red blood cell-mimic nanocatalyst triggering radical storm to augment cancer immunotherapy. Nano-Micro Lett. 14, 57 (2022). https://doi.org/10.1007/s40820-022-00801-z
  88. Z.-B. Wang, J. Xu, Better adjuvants for better vaccines: progress in adjuvant delivery systems, modifications, and adjuvant-antigen codelivery. Vaccines 8, 128 (2020). https://doi.org/10.3390/vaccines8010128
  89. J. Xia, Y. Miao, X. Wang, X. Huang, J. Dai, Recent progress of dendritic cell-derived exosomes (Dex) as an anti-cancer nanovaccine. Biomed. Pharmacother. 152, 113250 (2022). https://doi.org/10.1016/j.biopha.2022.113250
  90. M. Fan, H. Liu, H. Yan, R. Che, Y. Jin et al., A CAR T-inspiring platform based on antibody-engineered exosomes from antigen-feeding dendritic cells for precise solid tumor therapy. Biomaterials 282, 121424 (2022). https://doi.org/10.1016/j.biomaterials.2022.121424
  91. M. Wu, W. Wu, Y. Duan, X. Li, G. Qi et al., Photosensitizer-bacteria biohybrids promote photodynamic cancer cell ablation and intracellular protein delivery. Chem. Mater. 31, 7212–7220 (2019). https://doi.org/10.1021/acs.chemmater.9b01518
  92. Q. Hu, M. Wu, C. Fang, C. Cheng, M. Zhao et al., Engineering nanop-coated bacteria as oral DNA vaccines for cancer immunotherapy. Nano Lett. 15, 2732–2739 (2015). https://doi.org/10.1021/acs.nanolett.5b00570
  93. J. Chen, C.-Q. Sheng, C.-H. Zheng, Y.-W. Li, J.-G. Lv et al., Study of properties of VEGFR2 active site and binding mode of VEGFR2 and its inhibitors. Acta Chim. Sinica 65, 547 (2007)
  94. Z. Ye, L. Liang, H. Lu, Y. Shen, W. Zhou et al., Nanotechnology-employed bacteria-based delivery strategy for enhanced anticancer therapy. Int. J. Nanomedicine 16, 8069–8086 (2021). https://doi.org/10.2147/IJN.S329855
  95. C.-J. Chiang, P.-H. Huang, Metabolic engineering of probiotic Escherichia coli for cytolytic therapy of tumors. Sci. Rep. 11, 5853 (2021). https://doi.org/10.1038/s41598-021-85372-6
  96. S. Dai, H. Wang, F. Deng, Advances and challenges in enveloped virus-like p (VLP)-based vaccines. J. Immunol. Sci. 2, 36–41 (2018). https://www.immunologyresearchjournal.com/s/advances-and-challenges-in-enveloped-viruslike-p-vlpbased-vaccines.pdf
  97. J.C. Caldeira, M. Perrine, F. Pericle, F. Cavallo, Virus-like ps as an immunogenic platform for cancer vaccines. Viruses 12, 488 (2020). https://doi.org/10.3390/v12050488
  98. E. Tumban, P. Muttil, C.A.A. Escobar, J. Peabody, D. Wafula et al., Preclinical refinements of a broadly protective VLP-based HPV vaccine targeting the minor capsid protein, L2. Vaccine 33, 3346–3353 (2015). https://doi.org/10.1016/j.vaccine.2015.05.016
  99. F.-X. Ding, F. Wang, Y.-M. Lu, K. Li, K.-H. Wang et al., Multiepitope peptide-loaded virus-like ps as a vaccine against hepatitis B virus-related hepatocellular carcinoma. Hepatology 49, 1492–1502 (2009). https://doi.org/10.1002/hep.22816
  100. H. Ali, M. Akbar, B. Iqbal, F. Ali, N.K. Sharma et al., Virosome: an engineered virus for vaccine delivery. Saudi Pharm. J. 31, 752–764 (2023). https://doi.org/10.1016/j.jsps.2023.03.016
  101. U. Wiedermann, C. Wiltschke, J. Jasinska, M. Kundi, R. Zurbriggen et al., A virosomal formulated Her-2/neu multi-peptide vaccine induces Her-2/neu-specific immune responses in patients with metastatic breast cancer: a phase i study. Breast Cancer Res. Treat. 119, 673–683 (2010). https://doi.org/10.1007/s10549-009-0666-9
  102. R. Tenchov, R. Bird, A.E. Curtze, Q. Zhou, Lipid nanops─from liposomes to mRNA vaccine delivery, a landscape of research diversity and advancement. ACS Nano 15, 16982–17015 (2021). https://doi.org/10.1021/acsnano.1c04996
  103. Y. Yang, T. Yang, F. Chen, C. Zhang, B. Yin et al., Degradable magnetic nanoplatform with hydroxide ions triggered photoacoustic, MR imaging, and photothermal conversion for precise cancer theranostic. Nano Lett. 22, 3228–3235 (2022). https://doi.org/10.1021/acs.nanolett.1c04804
  104. J. Li, X. Chang, X. Chen, Z. Gu, F. Zhao et al., Toxicity of inorganic nanomaterials in biomedical imaging. Biotechnol. Adv. 32, 727–743 (2014). https://doi.org/10.1016/j.biotechadv.2013.12.009
  105. S.J. Soenen, P. Rivera-Gil, J.-M. Montenegro, W.J. Parak, S.C. De Smedt et al., Cellular toxicity of inorganic nanops: common aspects and guidelines for improved nanotoxicity evaluation. Nano Today 6, 446–465 (2011). https://doi.org/10.1016/j.nantod.2011.08.001
  106. F. Jia, W. Huang, Y. Yin, Y. Jiang, Q. Yang et al., Stabilizing RNA nanovaccines with transformable hyaluronan dynamic hydrogel for durable cancer immunotherapy. Adv. Funct. Mater. 33, 2204636 (2023). https://doi.org/10.1002/adfm.202204636
  107. K.S. Corbett, D.K. Edwards, S.R. Leist, O.M. Abiona, S. Boyoglu-Barnum et al., SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness. Nature 586, 567–571 (2020). https://doi.org/10.1038/s41586-020-2622-0
  108. M.N. Uddin, M.A. Roni, Challenges of storage and stability of mRNA-based COVID-19 vaccines. Vaccines 9, 1033 (2021). https://doi.org/10.3390/vaccines9091033
  109. H. Muramatsu, K. Lam, C. Bajusz, D. Laczkó, K. Karikó et al., Lyophilization provides long-term stability for a lipid nanop-formulated, nucleoside-modified mRNA vaccine. Mol. Ther. 30, 1941–1951 (2022). https://doi.org/10.1016/j.ymthe.2022.02.001
  110. Y. Gu, J. Duan, N. Yang, Y. Yang, X. Zhao, mRNA vaccines in the prevention and treatment of diseases. MedComm 3, e167 (2022). https://doi.org/10.1002/mco2.167
  111. C. Vasile, Polymeric nanomaterials: recent developments, properties and medical applications [B]. Polymeric nanomaterials in nanotherapeutics, Micro & Nano Technologies. (2019), p. 1–66. https://doi.org/10.1016/B978-0-12-813932-5.00001-7
  112. T.T. Spear, K. Nagato, M.I. Nishimura, Strategies to genetically engineer T cells for cancer immunotherapy. Cancer Immunol. Immunother. 65, 631–649 (2016). https://doi.org/10.1007/s00262-016-1842-5
  113. M. Kreutz, B. Giquel, Q. Hu, R. Abuknesha, S. Uematsu et al., Antibody-antigen-adjuvant conjugates enable co-delivery of antigen and adjuvant to dendritic cells in Cis but only have partial targeting specificity. PLoS ONE 7, e40208 (2012). https://doi.org/10.1371/journal.pone.0040208
  114. M. Yadav, S. Jhunjhunwala, Q.T. Phung, P. Lupardus, J. Tanguay et al., Predicting immunogenic tumour mutations by combining mass spectrometry and exome sequencing. Nature 515, 572–576 (2014). https://doi.org/10.1038/nature14001
  115. Q. Zhao, X. Dong, C. Zhu, Y. Zhang, C. Fang et al., DNA damage-encouraged Mn-As-based nanoreactors reshape intratumoral cell phenotypes to recover immune surveillance and potentiate anti-tumor immunity. Chem. Eng. J. 474, 145556 (2023). https://doi.org/10.1016/j.cej.2023.145556
  116. M. Sarikaya, C. Tamerler, A.K.-Y. Jen, K. Schulten, F. Baneyx, Molecular biomimetics: nanotechnology through biology. Nat. Mater. 2, 577–585 (2003). https://doi.org/10.1038/nmat964
  117. X. Liang, Y. Zhang, J. Zhou, Z. Bu, J. Liu et al., Tumor microenvironment-triggered intratumoral in situ construction of theranostic supramolecular self-assembly. Coord. Chem. Rev. 473, 214824 (2022). https://doi.org/10.1016/j.ccr.2022.214824
  118. R.M. Steinman, Decisions about dendritic cells: past, present, and future. Annu. Rev. Immunol. 30, 1–22 (2012). https://doi.org/10.1146/annurev-immunol-100311-102839
  119. K. Liu, M.C. Nussenzweig, Origin and development of dendritic cells. Immunol. Rev. 234, 45–54 (2010). https://doi.org/10.1111/j.0105-2896.2009.00879.x
  120. L. Wu, Y.-J. Liu, Development of dendritic-cell lineages. Immunity 26, 741–750 (2007). https://doi.org/10.1016/j.immuni.2007.06.006
  121. R.M. Steinman, M. Pack, K. Inaba, Dendritic cell development and maturation. Adv. Exp. Med. Biol. 417, 1–6 (1997). https://doi.org/10.1007/978-1-4757-9966-8_1
  122. L.E. Paulis, S. Mandal, M. Kreutz, C.G. Figdor, Dendritic cell-based nanovaccines for cancer immunotherapy. Curr. Opin. Immunol. 25, 389–395 (2013). https://doi.org/10.1016/j.coi.2013.03.001
  123. C. Macri, M. Paxman, D. Jenika, X.P. Lin, Z. Elahi et al., FcRn regulates antigen presentation in dendritic cells downstream of DEC205-targeted vaccines. npj Vaccines 9, 76 (2024). https://doi.org/10.1038/s41541-024-00854-8
  124. Y. van Kooyk, G.A. Rabinovich, Protein-glycan interactions in the control of innate and adaptive immune responses. Nat. Immunol. 9, 593–601 (2008). https://doi.org/10.1038/ni.f.203
  125. M. Kreutz, P.J. Tacken, C.G. Figdor, Targeting dendritic cells: why bother? Blood 121, 2836–2844 (2013). https://doi.org/10.1182/blood-2012-09-452078
  126. M. Tanaka, M. Saka-Tanaka, K. Ochi, K. Fujieda, Y. Sugiura et al., C-type lectin Mincle mediates cell death-triggered inflammation in acute kidney injury. J. Exp. Med. 217, e20192230 (2020). https://doi.org/10.1084/jem.20192230
  127. J.M. Jaynes, R. Sable, M. Ronzetti, W. Bautista, Z. Knotts et al., Mannose receptor (CD206) activation in tumor-associated macrophages enhances adaptive and innate antitumor immune responses. Sci. Transl. Med. 12, eaax6337 (2020). https://doi.org/10.1126/scitranslmed.aax6337
  128. M.H. Lahoud, F. Ahmet, J.-G. Zhang, S. Meuter, A.N. Policheni et al., Dec-205 is a cell surface receptor for cpg oligonucleotides. Proc. Natl. Acad. Sci. U.S.A. 109, 16270–16275 (2012). https://doi.org/10.1073/pnas.1208796109
  129. C. Petzold, S. Schallenberg, J.N.H. Stern, K. Kretschmer, Targeted antigen delivery to DEC-205⁺ dendritic cells for tolerogenic vaccination. Rev. Diabet. Stud. 9, 305–318 (2012). https://doi.org/10.1900/RDS.2012.9.305
  130. M. Guo, S. Gong, S. Maric, Z. Misulovin, M. Pack et al., A monoclonal antibody to the DEC-205 endocytosis receptor on human dendritic cells. Hum. Immunol. 61, 729–738 (2000). https://doi.org/10.1016/s0198-8859(00)00144-0
  131. M.O. Silva, B.S. Almeida, N.S. Sales, M.O. Diniz, L.R.M.M. Aps et al., Antigen delivery to DEC205+ dendritic cells induces immunological memory and protective therapeutic effects against HPV-associated tumors at different anatomical sites. Int. J. Biol. Sci. 17, 2944–2956 (2021). https://doi.org/10.7150/ijbs.57038
  132. C.D. Phung, T.H. Tran, H.T. Nguyen, T.T. Nguyen, J.H. Jeong et al., Nanovaccines silencing IL-10 production at priming phase for boosting immune responses to melanoma. J. Control. Release 338, 211–223 (2021). https://doi.org/10.1016/j.jconrel.2021.08.031
  133. B.E. Clausen, P. Stoitzner, Functional specialization of skin dendritic cell subsets in regulating T cell responses. Front. Immunol. 6, 534 (2015). https://doi.org/10.3389/fimmu.2015.00534
  134. C.G. Figdor, Y. van Kooyk, G.J. Adema, C-type lectin receptors on dendritic cells and Langerhans cells. Nat. Rev. Immunol. 2, 77–84 (2002). https://doi.org/10.1038/nri723
  135. S.W. Kashem, M. Haniffa, D.H. Kaplan, Antigen-presenting cells in the skin. Annu. Rev. Immunol. 35, 469–499 (2017). https://doi.org/10.1146/annurev-immunol-051116-052215
  136. L. Bellmann, H. Strandt, C. Zelle-Rieser, D. Ortner, C.H. Tripp et al., Targeted delivery of a vaccine protein to Langerhans cells in the human skin via the C-type lectin receptor Langerin. Eur. J. Immunol. 52, 1829–1841 (2022). https://doi.org/10.1002/eji.202149670
  137. G. Schreibelt, L.J. Klinkenberg, L.J. Cruz, P.J. Tacken, J. Tel et al., The C-type lectin receptor CLEC9A mediates antigen uptake and (cross-) presentation by human blood BDCA3+ myeloid dendritic cells. Blood 119, 2284–2292 (2012). https://doi.org/10.1182/blood-2011-08-373944
  138. S. Gou, S. Wang, W. Liu, G. Chen, D. Zhang et al., Adjuvant-free peptide vaccine targeting Clec9a on dendritic cells can induce robust antitumor immune response through Syk/IL-21 axis. Theranostics 11, 7308–7321 (2021). https://doi.org/10.7150/thno.56406
  139. F.E. Pearson, K.M. Tullett, I.M. Leal-Rojas, O.L. Haigh, K.-A. Masterman et al., Human CLEC9A antibodies deliver Wilms’ tumor 1 (WT1) antigen to CD141+ dendritic cells to activate naïve and memory WT1-specific CD8+ T cells. Clin. Transl. Immunology 9, e1141 (2020). https://doi.org/10.1002/cti2.1141
  140. J. Huang, J. Zhou, R. Ghinnagow, T. Seki, S. Iketani et al., Targeted co-delivery of tumor antigen and α-galactosylceramide to CD141+ dendritic cells induces a potent tumor antigen-specific human CD8+ T cell response in human immune system mice. Front. Immunol. 11, 2043 (2020). https://doi.org/10.3389/fimmu.2020.02043
  141. X. Feng, D. Liu, Z. Li, J. Bian, Bioactive modulators targeting STING adaptor in cGAS-STING pathway. Drug Discov. Today 25, 230–237 (2020). https://doi.org/10.1016/j.drudis.2019.11.007
  142. Y. Zhu, X. An, X. Zhang, Y. Qiao, T. Zheng et al., STING: a master regulator in the cancer-immunity cycle. Mol. Cancer 18, 152 (2019). https://doi.org/10.1186/s12943-019-1087-y
  143. S. Gou, W. Liu, S. Wang, G. Chen, Z. Chen et al., Engineered nanovaccine targeting Clec9a+ dendritic cells remarkably enhances the cancer immunotherapy effects of STING agonist. Nano Lett. 21, 9939–9950 (2021). https://doi.org/10.1021/acs.nanolett.1c03243
  144. M. Matsumoto, T. Tanaka, T. Kaisho, H. Sanjo, N.G. Copeland et al., A novel LPS-inducible C-type lectin is a transcriptional target of NF-IL6 in macrophages. J. Immunol. 163, 5039–5048 (1999). https://doi.org/10.4049/jimmunol.163.9.5039
  145. X. Luo, Q. Lian, W. Li, L. Chen, R. Zhang et al., Fully synthetic Mincle-dependent self-adjuvanting cancer vaccines elicit robust humoral and T cell-dependent immune responses and protect mice from tumor development. Chem. Sci. 12, 15998–16013 (2021). https://doi.org/10.1039/d1sc05736g
  146. E.M. Dangerfield, S. Ishizuka, K. Kodar, S. Yamasaki, M.S.M. Timmer et al., Chimeric NOD2 mincle agonists as vaccine adjuvants. J. Med. Chem. 67, 5373–5390 (2024). https://doi.org/10.1021/acs.jmedchem.3c01840
  147. P.R. Taylor, S. Gordon, L. Martinez-Pomares, The mannose receptor: linking homeostasis and immunity through sugar recognition. Trends Immunol. 26, 104–110 (2005). https://doi.org/10.1016/j.it.2004.12.001
  148. H.J.P. van der Zande, D. Nitsche, L. Schlautmann, B. Guigas, S. Burgdorf, The mannose receptor: from endocytic receptor and biomarker to regulator of (meta)inflammation. Front. Immunol. 12, 765034 (2021). https://doi.org/10.3389/fimmu.2021.765034
  149. G. Moku, S. Vangala, S.K. Gulla, V. Yakati, In vivo targeting of DNA vaccines to dendritic cells via the mannose receptor induces long-lasting immunity against melanoma. ChemBioChem 22, 523–531 (2021). https://doi.org/10.1002/cbic.202000364
  150. J. Chen, H. Fang, Y. Hu, J. Wu, S. Zhang et al., Combining mannose receptor mediated nanovaccines and gene regulated PD-L1 blockade for boosting cancer immunotherapy. Bioact. Mater. 7, 167–180 (2021). https://doi.org/10.1016/j.bioactmat.2021.05.036
  151. M. Vasquez, I. Simões, M. Consuegra-Fernández, F. Aranda, F. Lozano et al., Exploiting scavenger receptors in cancer immunotherapy: lessons from CD5 and SR-B1. Eur. J. Immunol. 47, 1108–1118 (2017). https://doi.org/10.1002/eji.201646903
  152. Y. Qian, H. Jin, S. Qiao, Y. Dai, C. Huang et al., Targeting dendritic cells in lymph node with an antigen peptide-based nanovaccine for cancer immunotherapy. Biomaterials 98, 171–183 (2016). https://doi.org/10.1016/j.biomaterials.2016.05.008
  153. W.-J. Shen, S. Azhar, F.B. Kraemer, SR-B1: a unique multifunctional receptor for cholesterol influx and efflux. Annu. Rev. Physiol. 80, 95–116 (2018). https://doi.org/10.1146/annurev-physiol-021317-121550
  154. L. Oliveira-Nascimento, P. Massari, L.M. Wetzler, The role of TLR2 in infection and immunity. Front. Immun. 3, 79 (2012). https://doi.org/10.3389/fimmu.2012.00079
  155. X. Zhao, R. Zhao, G. Nie, Nanocarriers based on bacterial membrane materials for cancer vaccine delivery. Nat. Protoc. 17, 2240–2274 (2022). https://doi.org/10.1038/s41596-022-00713-7
  156. N. Garçon, M. Van Mechelen, Recent clinical experience with vaccines using MPL- and QS-21-containing adjuvant systems. Expert Rev. Vaccines 10, 471–486 (2011). https://doi.org/10.1586/erv.11.29
  157. E. Vercammen, J. Staal, R. Beyaert, Sensing of viral infection and activation of innate immunity by toll-like receptor 3. Clin. Microbiol. Rev. 21, 13–25 (2008). https://doi.org/10.1128/CMR.00022-07
  158. R.A. Robinson, V.T. DeVita, H.B. Levy, S. Baron, S.P. Hubbard et al., A phase I-II trial of multiple-dose polyriboinosic-polyribocytidylic acid in patieonts with leukemia or solid tumors. J. Natl. Cancer Inst. 57, 599–602 (1976). https://doi.org/10.1093/jnci/57.3.599
  159. A.M. Salazar, H.B. Levy, S. Ondra, M. Kende, B. Scherokman et al., Long-term treatment of malignant gliomas with intramuscularly administered polyinosinic-polycytidylic acid stabilized with polylysine and carboxymethylcellulose: an open pilot study. Neurosurgery 38, 1096–1103 (1996). https://doi.org/10.1097/00006123-199606000-00006
  160. N. Butowski, K.R. Lamborn, B.L. Lee, M.D. Prados, T. Cloughesy et al., A North American brain tumor consortium phase II study of poly-ICLC for adult patients with recurrent anaplastic gliomas. J. Neurooncol 91, 183–189 (2009). https://doi.org/10.1007/s11060-008-9705-3
  161. H. Okada, P. Kalinski, R. Ueda, A. Hoji, G. Kohanbash et al., Induction of CD8+ T-cell responses against novel glioma-associated antigen peptides and clinical activity by vaccinations with{alpha}-type 1 polarized dendritic cells and polyinosinic-polycytidylic acid stabilized by lysine and carboxymethylcellulose in patients with recurrent malignant glioma. J. Clin. Oncol. 29, 330–336 (2011). https://doi.org/10.1200/JCO.2010.30.7744
  162. M.V. Dhodapkar, M. Sznol, B. Zhao, D. Wang, R.D. Carvajal et al., Induction of antigen-specific immunity with a vaccine targeting NY-ESO-1 to the dendritic cell receptor DEC-205. Sci. Transl. Med. 6, 23251 (2014). https://doi.org/10.1126/scitranslmed.3008068
  163. B.B. Gowen, M.-H. Wong, K.-H. Jung, A.B. Sanders, W.M. Mitchell et al., TLR3 is essential for the induction of protective immunity against Punta toro virus infection by the double-stranded RNA (dsRNA), poly(I: C12U), but not poly(I: C): differential recognition of synthetic dsRNA molecules. J. Immunol. 178, 5200–5208 (2007). https://doi.org/10.4049/jimmunol.178.8.5200
  164. K.A. Thompson, D.R. Strayer, P.D. Salvato, C.E. Thompson, N. Klimas et al., Results of a double-blind placebo-controlled study of the double-stranded RNA drug polyI: PolyC12U in the treatment of HIV infection. Eur. J. Clin. Microbiol. Infect. Dis. 15, 580–587 (1996). https://doi.org/10.1007/BF01709367
  165. T. Kaisho, S. Akira, Regulation of dendritic cell function through toll-like receptors. Curr. Mol. Med. 3, 759–771 (2003). https://doi.org/10.2174/1566524033479366
  166. H. Fang, B. Ang, X. Xu, X. Huang, Y. Wu et al., TLR4 is essential for dendritic cell activation and anti-tumor T-cell response enhancement by DAMPs released from chemically stressed cancer cells. Cell. Mol. Immunol. 11, 150–159 (2014). https://doi.org/10.1038/cmi.2013.59
  167. H. Zhang, X. You, X. Wang, L. Cui, Z. Wang et al., Delivery of mRNA vaccine with a lipid-like material potentiates antitumor efficacy through Toll-like receptor 4 signaling. Proc. Natl. Acad. Sci. U.S.A. 118, e2005191118 (2021). https://doi.org/10.1073/pnas.2005191118
  168. J.H. Fritz, S.E. Girardin, C. Fitting, C. Werts, D. Mengin-Lecreulx et al., Synergistic stimulation of human monocytes and dendritic cells by Toll-like receptor 4 and NOD1- and NOD2-activating agonists. Eur. J. Immunol. 35, 2459–2470 (2005). https://doi.org/10.1002/eji.200526286
  169. S.I. Gringhuis, J. den Dunnen, M. Litjens, B. van Het Hof, Y. van Kooyk et al., C-type lectin DC-SIGN modulates Toll-like receptor signaling via Raf-1 kinase-dependent acetylation of transcription factor NF-κ
  170. B. Immunity 26, 605–616 (2007). https://doi.org/10.1016/j.immuni.2007.03.012
  171. D. Yang, X. Luo, Q. Lian, L. Gao, C. Wang et al., Fully synthetic Tn-based three-component cancer vaccine using covalently linked TLR4 ligand MPLA and iNKT cell agonist KRN-7000 as built-in adjuvant effectively protects mice from tumor development. Acta Pharm. Sin. B 12, 4432–4445 (2022). https://doi.org/10.1016/j.apsb.2022.05.028
  172. T.C. Albershardt, J. Leleux, A.J. Parsons, J.E. Krull, P. Berglund et al., Intratumoral immune activation with TLR4 agonist synergizes with effector T cells to eradicate established murine tumors. npj Vaccines 5, 50 (2020). https://doi.org/10.1038/s41541-020-0201-x
  173. J.J. Baljon, A.J. Kwiatkowski, H.M. Pagendarm, P.T. Stone, A. Kumar et al., A cancer nanovaccine for co-delivery of peptide neoantigens and optimized combinations of STING and TLR4 agonists. ACS Nano 18, 6845–6862 (2024). https://doi.org/10.1021/acsnano.3c04471
  174. N. Kuzmich, K. Sivak, V. Chubarev, Y. Porozov, T. Savateeva-Lyubimova et al., TLR4 signaling pathway modulators as potential therapeutics in inflammation and sepsis. Vaccines 5, 34 (2017). https://doi.org/10.3390/vaccines5040034
  175. K. Crozat, B. Beutler, Tlr7: a new sensor of viral infection. Proc. Natl. Acad. Sci. U.S.A. 101, 6835–6836 (2004). https://doi.org/10.1073/pnas.0401347101
  176. H. Xia, M. Qin, Z. Wang, Y. Wang, B. Chen et al., A pH-/ enzyme-responsive nanop selectively targets endosomal toll-like receptors to potentiate robust cancer vaccination. Nano Lett. 22, 2978–2987 (2022). https://doi.org/10.1021/acs.nanolett.2c00185
  177. M. Liu, Y. Feng, Y. Lu, R. Huang, Y. Zhang et al., Lymph-targeted high-density lipoprotein-mimetic nanovaccine for multi-antigenic personalized cancer immunotherapy. Sci. Adv. 10, eadk2444 (2024). https://doi.org/10.1126/sciadv.adk2444
  178. C. Rolfo, E. Giovannetti, P. Martinez, S. McCue, A. Naing, Applications and clinical trial landscape using Toll-like receptor agonists to reduce the toll of cancer. npj Precis. Oncol. 7, 26 (2023). https://doi.org/10.1038/s41698-023-00364-1
  179. B.-D. Zhang, J.-J. Wu, W.-H. Li, H.-G. Hu, L. Zhao et al., STING and TLR7/8 agonists-based nanovaccines for synergistic antitumor immune activation. Nano Res. 15, 6328–6339 (2022). https://doi.org/10.1007/s12274-022-4282-x
  180. N. Wang, G. Zhang, P. Zhang, K. Zhao, Y. Tian et al., Vaccination of TLR7/8 agonist-conjugated antigen nanops for cancer immunotherapy. Adv. Healthcare Mater. 12, 2300249 (2023). https://doi.org/10.1002/adhm.202300249
  181. Y. Kumagai, O. Takeuchi, S. Akira, Tlr9 as a key receptor for the recognition of DNA. Adv. Drug Deliv. Rev. 60, 795–804 (2008). https://doi.org/10.1016/j.addr.2007.12.004
  182. P. Chen, D. Wang, Y. Wang, L. Zhang, Q. Wang et al., Maximizing TLR9 activation in cancer immunotherapy with dual-adjuvanted spherical nucleic acids. Nano Lett. 22, 4058–4066 (2022). https://doi.org/10.1021/acs.nanolett.2c00723
  183. Y. Wang, S.-L. Qiao, J. Wang, M.-Z. Yu, N.-N. Wang et al., Engineered CpG-loaded nanorobots drive autophagy-mediated immunity for TLR9-positive cancer therapy. Adv. Mater. 36, e2306248 (2024). https://doi.org/10.1002/adma.202306248
  184. Y. Ma, L. Galluzzi, L. Zitvogel, G. Kroemer, Autophagy and cellular immune responses. Immunity 39, 211–227 (2013). https://doi.org/10.1016/j.immuni.2013.07.017
  185. G.B. Mackaness, R.V. Blanden, Cellular immunity. Prog. Allergy 11, 89–140 (1967). https://doi.org/10.1159/000287245
  186. J. Zhang, B. Fan, G. Cao, W. Huang, F. Jia et al., Direct presentation of tumor-associated antigens to induce adaptive immunity by personalized dendritic cell-mimicking nanovaccines. Adv. Mater. 34, e2205950 (2022). https://doi.org/10.1002/adma.202205950
  187. C. Liu, X. Liu, X. Xiang, X. Pang, S. Chen et al., A nanovaccine for antigen self-presentation and immunosuppression reversal as a personalized cancer immunotherapy strategy. Nat. Nanotechnol. 17, 531–540 (2022). https://doi.org/10.1038/s41565-022-01098-0
  188. K. Wang, X. Zhang, H. Ye, X. Wang, Z. Fan et al., Biomimetic nanovaccine-mediated multivalent IL-15 self-transpresentation (MIST) for potent and safe cancer immunotherapy. Nat. Commun. 14, 6748 (2023). https://doi.org/10.1038/s41467-023-42155-z
  189. A. Fusco, M. Fedele, Roles of HMGA proteins in cancer. Nat. Rev. Cancer 7, 899–910 (2007). https://doi.org/10.1038/nrc2271
  190. M.J. van de Vijver, J.L. Peterse, W.J. Mooi, P. Wisman, J. Lomans et al., Neu-protein overexpression in breast cancer. Association with comedo-type ductal carcinoma in situ and limited prognostic value in stage II breast cancer. New Engl. J. Med. 319, 1239–1245 (1988). https://doi.org/10.1056/NEJM198811103191902
  191. J.B. Welsh, L.M. Sapinoso, S.G. Kern, D.A. Brown, T. Liu et al., Large-scale delineation of secreted protein biomarkers overexpressed in cancer tissue and serum. Proc. Natl. Acad. Sci. U.S.A. 100, 3410–3415 (2003). https://doi.org/10.1073/pnas.0530278100
  192. K.R. Kampen, Membrane proteins: the key players of a cancer cell. J. Membr. Biol. 242, 69–74 (2011). https://doi.org/10.1007/s00232-011-9381-7
  193. E. de Jong, A. Kocer, Current methods for identifying plasma membrane proteins as cancer biomarkers. Membranes 13, 409 (2023). https://doi.org/10.3390/membranes13040409
  194. D. Grimm, J. Bauer, J. Pietsch, M. Infanger, J. Eucker et al., Diagnostic and therapeutic use of membrane proteins in cancer cells. Curr. Med. Chem. 18, 176–190 (2011). https://doi.org/10.2174/092986711794088344
  195. J.F. Curtin, N. Liu, M. Candolfi, W. Xiong, H. Assi et al., HMGB1 mediates endogenous TLR2 activation and brain tumor regression. PLoS Med. 6, e10 (2009). https://doi.org/10.1371/journal.pmed.1000010
  196. E. Vénéreau, C. Ceriotti, M.E. Bianchi, DAMPs from cell death to new life. Front. Immunol. 6, 422 (2015). https://doi.org/10.3389/fimmu.2015.00422
  197. T. Yamazaki, D. Hannani, V. Poirier-Colame, S. Ladoire, C. Locher et al., Defective immunogenic cell death of HMGB1-deficient tumors: compensatory therapy with TLR4 agonists. Cell Death Differ. 21, 69–78 (2014). https://doi.org/10.1038/cdd.2013.72
  198. I.E. Dumitriu, M.E. Bianchi, M. Bacci, A.A. Manfredi, P. Rovere-Querini, The secretion of HMGB1 is required for the migration of maturing dendritic cells. J. Leukoc. Biol. 81, 84–91 (2007). https://doi.org/10.1189/jlb.0306171
  199. E. Berney, N. Sabnis, M. Panchoo, S. Raut, R. Dickerman et al., The SR-B1 receptor as a potential target for treating glioblastoma. J. Oncol. 2019, 1805841 (2019). https://doi.org/10.1155/2019/1805841
  200. P. Kadiyala, D. Li, F.M. Nuñez, D. Altshuler, R. Doherty et al., High-density lipoprotein-mimicking nanodiscs for chemo-immunotherapy against glioblastoma multiforme. ACS Nano 13, 1365–1384 (2019). https://doi.org/10.1021/acsnano.8b06842
  201. L. Bello, M. Francolini, P. Marthyn, J. Zhang, R.S. Carroll et al., αvβ3 and αvβ5 integrin expression in glioma periphery. Neurosurgery 49, 380–389 (2001). https://doi.org/10.1097/00006123-200108000-00022
  202. C. Böger, V.S. Warneke, H.-M. Behrens, H. Kalthoff, S.L. Goodman et al., Integrins αvβ3 and αvβ5 as prognostic, diagnostic, and therapeutic targets in gastric cancer. Gastric Cancer 18, 784–795 (2015). https://doi.org/10.1007/s10120-014-0435-2
  203. T. Hurtado de Mendoza, E.S. Mose, G.P. Botta, G.B. Braun, V.R. Kotamraju et al., Tumor-penetrating therapy for β5 integrin-rich pancreas cancer. Nat. Commun. 12, 1541 (2021). https://doi.org/10.1038/s41467-021-21858-1
  204. N. Ding, Z. Zou, H. Sha, S. Su, H. Qian et al., iRGD synergizes with PD-1 knockout immunotherapy by enhancing lymphocyte infiltration in gastric cancer. Nat. Commun. 10, 1336 (2019). https://doi.org/10.1038/s41467-019-09296-6
  205. S. Zhou, F. Meng, S. Du, H. Qian, N. Ding et al., Bifunctional iRGD-anti-CD3 enhances antitumor potency of T cells by facilitating tumor infiltration and T-cell activation. J. Immunother. Cancer 9, e001925 (2021). https://doi.org/10.1136/jitc-2020-001925
  206. Y. Song, M. Xu, Y. Li, Y. Li, W. Gu et al., An iRGD peptide fused superantigen mutant induced tumor-targeting and T lymphocyte infiltrating in cancer immunotherapy. Int. J. Pharm. 586, 119498 (2020). https://doi.org/10.1016/j.ijpharm.2020.119498
  207. T. Mitsudomi, Y. Yatabe, Epidermal growth factor receptor in relation to tumor development: EGFR gene and cancer. FEBS J. 277, 301–308 (2010). https://doi.org/10.1111/j.1742-4658.2009.07448.x
  208. D.A. Sabbah, R. Hajjo, K. Sweidan, Review on epidermal growth factor receptor (EGFR) structure, signaling pathways, interactions, and recent updates of EGFR inhibitors. Curr. Top. Med. Chem. 20, 815–834 (2020). https://doi.org/10.2174/1568026620666200303123102
  209. A. De Luca, A. Carotenuto, A. Rachiglio, M. Gallo, M.R. Maiello et al., The role of the EGFR signaling in tumor microenvironment. J. Cell. Physiol. 214, 559–567 (2008). https://doi.org/10.1002/jcp.21260
  210. Q. Cheng, X. Shi, M. Han, G. Smbatyan, H.-J. Lenz et al., Reprogramming exosomes as nanoscale controllers of cellular immunity. J. Am. Chem. Soc. 140, 16413–16417 (2018). https://doi.org/10.1021/jacs.8b10047
  211. G. Lammering, T.H. Hewit, W.T. Hawkins, J.N. Contessa, D.B. Reardon et al., Epidermal growth factor receptor as a genetic therapy target for carcinoma cell radiosensitization. J. Natl. Cancer Inst. 93, 921–929 (2001). https://doi.org/10.1093/jnci/93.12.921
  212. M.S. Alghamri, K. Banerjee, A.A. Mujeeb, A. Mauser, A. Taher et al., Systemic delivery of an adjuvant CXCR4-CXCL12 signaling inhibitor encapsulated in synthetic protein nanops for glioma immunotherapy. ACS Nano 16, 8729–8750 (2022). https://doi.org/10.1021/acsnano.1c07492
  213. D.M. Pardoll, The blockade of immune checkpoints in cancer immunotherapy. Nat. Rev. Cancer 12, 252–264 (2012). https://doi.org/10.1038/nrc3239
  214. P. Sharma, J.P. Allison, The future of immune checkpoint therapy. Science 348, 56–61 (2015). https://doi.org/10.1126/science.aaa8172
  215. P. Sharma, J.P. Allison, Dissecting the mechanisms of immune checkpoint therapy. Nat. Rev. Immunol. 20, 75–76 (2020). https://doi.org/10.1038/s41577-020-0275-8
  216. J.M. Fritz, M.J. Lenardo, Development of immune checkpoint therapy for cancer. J. Exp. Med. 216, 1244–1254 (2019). https://doi.org/10.1084/jem.20182395
  217. S. Chikuma. CTLA-4, an essential immune-checkpoint for T-cell activation. Current Topics in Microbiology and Immunology. (Springer International Publishing, 2017), pp. 99–126. https://doi.org/10.1007/82_2017_61
  218. J.B.A.G. Haanen, C. Robert, Immune checkpoint inhibitors. Progress in Tumor Research. S. Karger AG, (2015), pp. 55–66 https://doi.org/10.1159/000437178
  219. C. Peres, A.I. Matos, B. Carreira, L.I.F. Moura, R. Kleiner et al., Multifunctional nanovaccine sensitizes breast cancer to immune checkpoint therapy. Adv. Funct. Mater. 34, 2401749 (2024). https://doi.org/10.1002/adfm.202401749
  220. P. Zhao, Y. Xu, W. Ji, L. Li, L. Qiu et al., Hybrid membrane nanovaccines combined with immune checkpoint blockade to enhance cancer immunotherapy. Int. J. Nanomedicine 17, 73–89 (2022). https://doi.org/10.2147/IJN.S346044
  221. H. Liu, H. Chen, Z. Liu, Z. Le, T. Nie et al., Therapeutic nanovaccines sensitize EBV-associated tumors to checkpoint blockade therapy. Biomaterials 255, 120158 (2020). https://doi.org/10.1016/j.biomaterials.2020.120158
  222. C. Li, R. Clauson, L.F. Bugada, F. Ke, B. He et al., Antigen-clustered nanovaccine achieves long-term tumor remission by promoting B/CD 4 T cell crosstalk. ACS Nano 18, 9584–9604 (2024). https://doi.org/10.1021/acsnano.3c13038
  223. R.E. Hollingsworth, K. Jansen, Turning the corner on therapeutic cancer vaccines. npj Vaccines 4, 7 (2019). https://doi.org/10.1038/s41541-019-0103-y
  224. T. Jiang, T. Shi, H. Zhang, J. Hu, Y. Song et al., Tumor neoantigens: from basic research to clinical applications. J. Hematol. Oncol. 12, 93 (2019). https://doi.org/10.1186/s13045-019-0787-5
  225. A. Sette, S. Crotty, Adaptive immunity to SARS-CoV-2 and COVID-19. Cell 184, 861–880 (2021). https://doi.org/10.1016/j.cell.2021.01.007
  226. J.S. Heitmann, T. Bilich, C. Tandler, A. Nelde, Y. Maringer et al., A COVID-19 peptide vaccine for the induction of SARS-CoV-2 T cell immunity. Nature 601, 617–622 (2022). https://doi.org/10.1038/s41586-021-04232-5
  227. R. Keeton, M.B. Tincho, A. Ngomti, R. Baguma, N. Benede et al., T cell responses to SARS-CoV-2 spike cross-recognize Omicron. Nature 603, 488–492 (2022). https://doi.org/10.1038/s41586-022-04460-3
  228. A. Tarke, C.H. Coelho, Z. Zhang, J.M. Dan, E.D. Yu et al., SARS-CoV-2 vaccination induces immunological T cell memory able to cross-recognize variants from Alpha to Omicron. Cell 185, 847-859.e11 (2022). https://doi.org/10.1016/j.cell.2022.01.015
  229. Z. Zhang, J. Mateus, C.H. Coelho, J.M. Dan, C.R. Moderbacher et al., Humoral and cellular immune memory to four COVID-19 vaccines. Cell 185, 2434-2451.e17 (2022). https://doi.org/10.1016/j.cell.2022.05.022
  230. A.M. Scott, J.D. Wolchok, L.J. Old, Antibody therapy of cancer. Nat. Rev. Cancer 12, 278–287 (2012). https://doi.org/10.1038/nrc3236
  231. V.R. Gómez Román, J.C. Murray, L.M. Weiner, Antibody-dependent cellular cytotoxicity (ADCC). Antibody Fc. (Elsevier, 2014), pp. 1–27. https://doi.org/10.1016/b978-0-12-394802-1.00001-7
  232. M.Z. Tay, K. Wiehe, J. Pollara, Antibody-dependent cellular phagocytosis in antiviral immune responses. Front. Immunol. 10, 332 (2019). https://doi.org/10.3389/fimmu.2019.00332
  233. D. Gancz, Z. Fishelson, Cancer resistance to complement-dependent cytotoxicity (CDC): problem-oriented research and development. Mol. Immunol. 46, 2794–2800 (2009). https://doi.org/10.1016/j.molimm.2009.05.009
  234. B.A. Helmink, S.M. Reddy, J. Gao, S. Zhang, R. Basar et al., B cells and tertiary lymphoid structures promote immunotherapy response. Nature 577, 549–555 (2020). https://doi.org/10.1038/s41586-019-1922-8
  235. S.S. Kim, W.A. Sumner, S. Miyauchi, E.E.W. Cohen, J.A. Califano et al., Role of B cells in responses to checkpoint blockade immunotherapy and overall survival of cancer patients. Clin. Cancer Res. 27, 6075–6082 (2021). https://doi.org/10.1158/1078-0432.ccr-21-0697
  236. D.A. Barth, S. Stanzer, J.A. Spiegelberg, T. Bauernhofer, G. Absenger et al., Patterns of peripheral blood B-cell subtypes are associated with treatment response in patients treated with immune checkpoint inhibitors: a prospective longitudinal pan-cancer study. Front. Immunol. 13, 840207 (2022). https://doi.org/10.3389/fimmu.2022.840207
  237. F. Petitprez, A. de Reyniès, E.Z. Keung, T.W.-W. Chen, C.-M. Sun et al., B cells are associated with survival and immunotherapy response in sarcoma. Nature 577, 556–560 (2020). https://doi.org/10.1038/s41586-019-1906-8
  238. V. Trujillo-Alonso, E.C. Pratt, H. Zong, A. Lara-Martinez, C. Kaittanis et al., FDA-approved ferumoxytol displays anti-leukaemia efficacy against cells with low ferroportin levels. Nat. Nanotechnol. 14, 616–622 (2019). https://doi.org/10.1038/s41565-019-0406-1
  239. P. Xie, S.T. Yang, Y. Huang, C. Zeng, Q. Xin et al., Carbon nanops-Fe(II) complex for efficient tumor inhibition with low toxicity by amplifying oxidative stress. ACS Appl. Mater. Interfaces 12(26), 29094–29102 (2020). https://doi.org/10.1021/acsami.0c07617
  240. Y.H. Ko, EBV and human cancer. Exp. Mol. Med. 47, e130 (2015). https://doi.org/10.1038/emm.2014.109
  241. D. Srikrishna, K. Sachsenmeier, We need to bring R0 < 1 to treat cancer too. Genome Med. 13, 120 (2021). https://doi.org/10.1186/s13073-021-00940-9
  242. D. Sarker, R. Plummer, T. Meyer, M.H. Sodergren, B. Basu et al., MTL-CEBPA, a small activating RNA therapeutic upregulating C/EBP-α, in patients with advanced liver cancer: a first-in-human, multicenter, open-label, phase I trial. Clin. Cancer Res. 26, 3936–3946 (2020). https://doi.org/10.1158/1078-0432.CCR-20-0414
  243. N. Hilf, S. Kuttruff-Coqui, K. Frenzel, V. Bukur, S. Stevanović et al., Actively personalized vaccination trial for newly diagnosed glioblastoma. Nature 565, 240–245 (2019). https://doi.org/10.1038/s41586-018-0810-y
  244. S.N. Bhatia, X. Chen, M.A. Dobrovolskaia, T. Lammers, Cancer nanomedicine. Nat. Rev. Cancer 22, 550–556 (2022). https://doi.org/10.1038/s41568-022-00496-9
  245. T.A. Qiu, M.J. Gallagher, N.V. Hudson-Smith, J. Wu, M.O.P. Krause et al., Research highlights: unveiling the mechanisms underlying nanop-induced ROS generation and oxidative stress. Environ. Sci. Nano 3, 940–945 (2016). https://doi.org/10.1039/C6EN90021F
  246. S.E. Lehman, A.S. Morris, P.S. Mueller, A.K. Salem, V.H. Grassian et al., Silica nanop-generated ROS as a predictor of cellular toxicity: mechanistic insights and safety by design. Environ. Sci. Nano 3, 56–66 (2016). https://doi.org/10.1039/C5EN00179J
  247. Y. Li, W. Zhang, J. Niu, Y. Chen, Mechanism of photogenerated reactive oxygen species and correlation with the antibacterial properties of engineered metal-oxide nanops. ACS Nano 6, 5164–5173 (2012). https://doi.org/10.1021/nn300934k
  248. D. Bitounis, E. Jacquinet, M.A. Rogers, M.M. Amiji, Strategies to reduce the risks of mRNA drug and vaccine toxicity. Nat. Rev. Drug Discov. 23, 281–300 (2024). https://doi.org/10.1038/s41573-023-00859-3
  249. J. Xu, D.H.C. Wong, J.D. Byrne, K. Chen, C. Bowerman et al., Future of the p replication in nonwetting templates (PRINT) technology. Angew. Chem. Int. Ed. 52, 6580–6589 (2013). https://doi.org/10.1002/anie.201209145
  250. J.-M. Lim, A. Swami, L.M. Gilson, S. Chopra, S. Choi et al., Ultra-high throughput synthesis of nanops with homogeneous size distribution using a coaxial turbulent jet mixer. ACS Nano 8, 6056–6065 (2014). https://doi.org/10.1021/nn501371n
  251. D. Wang, M. Zhang, Y. Zhang, G. Qiu, J. Chen et al., Intrap double-scattering-decoded sonogenetics for augmenting immune checkpoint blockade and CAR-T therapy. Adv. Sci. 9, e2203106 (2022). https://doi.org/10.1002/advs.202203106
  252. L. Lei, S. Cai, Y. Zhang, L. Yang, J. Deng et al., Structure inversion-bridged sequential amino acid metabolism disturbance potentiates photodynamic-evoked immunotherapy. Adv. Funct. Mater. 32, 2103394 (2022). https://doi.org/10.1002/adfm.202103394
  253. H. Zhou, C. Zhu, Q. Zhao, J. Ni, H. Zhang et al., Wrecking neutrophil extracellular traps and antagonizing cancer-associated neurotransmitters by interpenetrating network hydrogels prevent postsurgical cancer relapse and metastases. Bioact. Mater. 39, 14–24 (2024). https://doi.org/10.1016/j.bioactmat.2024.05.022
  254. D. Wang, M. Zhang, G. Qiu, C. Rong, X. Zhu et al., Extracellular matrix viscosity reprogramming by in situ Au bioreactor-boosted microwavegenetics disables tumor escape in CAR-T immunotherapy. ACS Nano 17, 5503–5516 (2023). https://doi.org/10.1021/acsnano.2c10845
  255. X. Dong, H. Liu, C. Fang, Y. Zhang, Q. Yang et al., Sonocatalytic on colysis microbiota curb intrinsic microbiota lactate metabolism and blockade CD24-Siglec10 immune escape to revitalize immunological surveillance. Biomaterials 311, 122662 (2024). https://doi.org/10.1016/j.biomaterials.2024.122662
  256. R. Jiao, X. Lin, Q. Zhang, Y. Zhang, W. Qin et al., Anti-tumor immune potentiation targets-engineered nanobiotechnologies: design principles and applications. Prog. Mater. Sci. 142, 101230 (2024). https://doi.org/10.1016/j.pmatsci.2023.101230
  257. C. Fang, G. Xiao, T. Wang, L. Song, B. Peng et al., Emerging nano-/ biotechnology drives oncolytic virus-activated and combined cancer immunotherapy. Research (Wash D C) 6, 0108 (2023). https://doi.org/10.34133/research.0108
Read More
Author biographies are not available.
Download this PDF file
PDF
Statistic
Read Counter : 1883 Download : 1419

Most read articles by the same author(s)